secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001193125-21-247694
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021
--------------------------------------------------------------------------------

- Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.
- R&D expenses $15.5M (up from $13.4M) driven by SGT-001 manufacturing and clinical costs.
- Cash, cash equivalents and securities $249M as of June 30, 2021; runway into Q4 2022.
- IGNITE DMD trial: next patient dosing anticipated Q4 2021; no new safety findings in patients 1-8 over 90 days to >3 years.
- Targeting IND submission for next-generation SGT-003 in early-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/0001193125-21-247694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/d200956d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-247694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer